Cbn (cannabinol) pharmacology
Pro Research Analysisby 
Searched over 200M research papers
Cannabinol (CBN) Pharmacology: Receptor Interactions and Mechanisms
Cannabinol (CBN) is a non-psychoactive cannabinoid found in Cannabis sativa, distinct from the more widely known THC and CBD. CBN primarily interacts with the endocannabinoid system (ECS) by acting as a partial agonist at both CB1 and CB2 receptors, modulating their activity and influencing downstream signaling pathways. These interactions affect physiological processes such as pain perception, inflammation, immune response, and neuroprotection. Beyond the ECS, CBN also interacts with non-cannabinoid targets, including transient receptor potential (TRP) channels, peroxisome proliferator-activated receptors (PPARs), and serotonin receptors, contributing to its effects on pain, inflammation, and mood regulation 128.
Anti-Inflammatory and Antioxidant Properties of CBN
CBN demonstrates significant anti-inflammatory and antioxidant properties. It reduces oxidative stress by scavenging reactive oxygen species (ROS) and inhibits inflammatory mediators, which may contribute to its neuroprotective effects and potential in treating neurodegenerative disorders. In human keratinocytes, CBN increases the expression and activity of CB1 and TRPV1 receptors, modulates the metabolism of endocannabinoids, and reduces the release of pro-inflammatory cytokines while increasing anti-inflammatory cytokines. These effects are partly mediated by TRPV1 and involve modulation of the MAPK signaling pathway 18.
Analgesic and Neuropathic Pain Modulation
CBN has been shown to inhibit voltage-dependent sodium (Nav) channels in dorsal root ganglion neurons, leading to reduced neuronal excitability. This functionally selective inhibition of Nav currents suggests that CBN may be useful for neuropathic pain management, adding a new dimension to its pharmacological profile beyond traditional cannabinoid receptor interactions .
Anticancer Activity of CBN
CBN exhibits anticancer properties by inhibiting cell growth, inducing apoptosis, and causing cell cycle arrest in various cancer cell lines, including acute myeloid leukemia, glioma, liver, and breast cancer cells. These effects are associated with modulation of cannabinoid receptors (such as CB2, GPR18, and GPR55), inhibition of the ERK1/2 and AKT pathways, and downregulation of cell cycle regulators like p21, p27, CDK1, CDK2, and cyclin E1. In leukemia cells, CBN’s anticancer effects may involve activation of p53-associated signaling pathways 310.
CBN and Sleep: Evidence and Clinical Trials
CBN is often marketed for its sleep-promoting effects, but current evidence from human studies is limited and inconclusive. Most clinical research is dated, with small sample sizes and lacking robust methodology. Recent and ongoing randomized controlled trials are investigating the effects of CBN on sleep continuity, sleep architecture, and next-day function in individuals with insomnia disorder, but results are still pending. Thus, there is currently insufficient clinical evidence to support claims that CBN alone improves sleep, and more rigorous studies are needed 459.
Safety and Tolerability of CBN
Animal studies indicate that CBN is well tolerated at pharmacological doses, with no significant adverse effects on behavior, body mass, or blood chemistry. The only notable finding was a reduction in eosinophil counts at higher doses, with no evidence of liver toxicity .
Antimicrobial Activity
CBN also shows potential antimicrobial activity against various bacteria and fungi, including methicillin-resistant Staphylococcus aureus (MRSA). The mechanisms may involve disruption of microbial cell membranes and interference with biofilm formation, though further research is needed to clarify these effects .
Conclusion
CBN is a multifaceted cannabinoid with diverse pharmacological actions, including modulation of the endocannabinoid system, anti-inflammatory and antioxidant effects, analgesic and anticancer properties, and potential antimicrobial activity. While preclinical data are promising, especially for pain, inflammation, and cancer, robust clinical evidence—particularly for sleep-related claims—remains limited. Ongoing research will help clarify CBN’s therapeutic potential and safety profile in humans.
Sources and full results
Most relevant research papers on this topic